NCT06513624RECRUITINGanonymous

A Phase 1B Investigator Initiated Study To Evaluate The Preliminary Activity, Safety And Tolerability Of ETC-159 In Combination With Pembrolizumab In Advanced MSS/pMMR Ovarian Cancers.

Sponsor

Source record

National University Hospital, Singapore

Phase

Source record

PHASE1

Modality

AI-normalized

small molecule

Target

AI-normalized

ETC-159, Pembrolizumab, Denosumab / Zoledronic Acid

Indication / condition

AI-normalized

With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer

Intervention

Source record

ETC-159, Pembrolizumab, Denosumab / Zoledronic Acid

Related intelligence directories

Indication directory: With MSS/pMMR Advanced Modality directory: small molecule Target directory: ETC-159

Source & freshness

Source record

NCT ID

NCT06513624

Original source

ClinicalTrials.gov

Source last updated

Jul 25, 2025

Ingested at

Jun 19, 2026

Internal sync

Jun 19, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT06513624

Title

A Phase 1B Investigator Initiated Study To Evaluate The Preliminary Activity, Safety And Tolerability Of ETC-159 In Combination With Pembrolizumab In Advanced MSS/pMMR Ovarian Cancers.

Sponsor

National University Hospital, Singapore

Status

RECRUITING

Phase

PHASE1

Condition raw

With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer

Condition normalized

With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer

Modality raw

small molecule

Modality normalized

small molecule

Target raw

ETC-159, Pembrolizumab, Denosumab / Zoledronic Acid

Target normalized

ETC-159, Pembrolizumab, Denosumab / Zoledronic Acid

Interventions

ETC-159, Pembrolizumab, Denosumab / Zoledronic Acid

Public preview

Source record

This is an open-label, single-arm, investigator-initiated study conceived as a dose expansion cohort of the study D3-002, which evaluated ETC-159 in combination with pembrolizumab in solid tumors.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase 1B Investigator Initiated Study To Evaluate The Preliminary Activity, Safety And Tolerability Of ETC-159 In Combination With Pembrolizumab In Advanced MSS/pMMR Ovarian Cancers.

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 19, 2026

NCT ID

NCT06513624

Status

RECRUITING

Phase

PHASE1

Sponsor

National University Hospital, Singapore

Executive brief

Investment-Ready Snapshot

This is an open-label, single-arm, investigator-initiated study conceived as a dose expansion cohort of the study D3-002, which evaluated ETC-159 in combination with pembrolizumab in solid tumors.

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedJul 25, 2025

Internal syncJun 19, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT06513624

Indication

With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer

Modality

small molecule

Target

ETC-159, Pembrolizumab, Denosumab / Zoledronic Acid

Intervention

ETC-159, Pembrolizumab, Denosumab / Zoledronic Acid

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.